The therapeutic potential of CETP inhibitors: a patent review

References

• Jafri H, Alsheikh-Ali AA, Karas RH. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med. 2010;153(12):800–808.
   PubMed Web of Science ®Google Scholar
• De Backer G. European guidelines on cardiovascular disease prevention in clinical practice third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur Heart J. 2003;24(17):1601–1610.
   PubMed Web of Science ®Google Scholar
• Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. New Engl J Med. 2007;357:1301–1310.
   PubMed Web of Science ®Google Scholar
• Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL densitynsubfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001;104:1108–1113.
   PubMed Web of Science ®Google Scholar
• McGovern PG, Pankow JS, Shahar K, et al. Recent trends in acute coronary heart disease – mortality, morbidity, medical care, and risk factors. N Eng J Med. 1996;334:884–890.
   PubMed Web of Science ®Google Scholar
• Curb JD, Abbott RD, Rodriguez BL, et al. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res. 2004;45(5):948–953.
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681.
   PubMed Web of Science ®Google Scholar
• Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American diabetes association and the American college of cardiology foundation. Diabetes Care. 2008;31(4):811–822.
   PubMed Web of Science ®Google Scholar
• Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol. 2013;61(4):440–446.
   PubMed Web of Science ®Google Scholar
• Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Eng J Med. 2007;357:1301–1310.
   PubMed Web of Science ®Google Scholar
• Gotto AM Jr. Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report. Circulation. 2001;103(17):2213–2218.
   PubMed Web of Science ®Google Scholar
• Gotto AM Jr, Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J Am Coll Cardiol. 2004;43(5):717.
   PubMed Web of Science ®Google Scholar
• Rubins HB, Fye CL, Schectman G, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Eng J Med. 1999;341(6):410.
   PubMed Web of Science ®Google Scholar
• Shepherd J, Betteridge J, Van GL. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European consensus panel. Curr Med Res Opin. 2005;21(5):665–682.
   PubMed Web of Science ®Google Scholar
• Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res. 1993;34(8):1255–1274.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Brewer HB Jr, Chapman MJ, et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscl Throm Vas. 2003;23(2):160.
   Google Scholar
• Qiu X, Mistry A, Ammirati MJ, et al. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat Struct Mol Biol. 2007;14(2):106.
   PubMed Web of Science ®Google Scholar
• Liu S, Mistry A, Reynolds JM, et al. Crystal structures of cholesteryl ester transfer protein in complex with inhibitors. J Biol Chem. 2012;287(44):37321.
   PubMed Web of Science ®Google Scholar
• Novartis A-G, Switz. Organic compounds. US20120264773A1. 2012.
   Google Scholar
• Novartis A-G, Switz. Preparation of 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis. WO2009071509A1. 2009.
   Google Scholar
• Novartis AG, Switz. 4-Benzylamino-1-carboxyacyl-piperdine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis. US2009059943A1. 2009.
   Google Scholar
• Novartis A-G, Switz. 4-Benzylamino-1-carboxyacyl-piperdine derivatives as CETP inhibitors. US8440682B2. 2013.
   Google Scholar
• Novartis A-G, Switz. 4-Benzylamino-1-carboxyacyl-piperdine derivatives as CETP inhibitors. US8193349B2. 2012.
   Google Scholar
• Novartis AG, Switz. 4-Benzylamino-1-carboxyacyl-piperdine derivatives as CETP inhibitors useful for the treament of diseases such as hyperlipidemia or arteriosclerosis. CN101910150A. 2010.
   Google Scholar
• Yamada K, Brousseau M, Honma W, et al. Discovery of a novel piperidine-based inhibitor of Cholesteryl Ester Transfer Protein (CETP) that retains activity in hypertriglyceridemic plasma. J Med Chem. 2017;60(20):8466–8481.
   PubMed Web of Science ®Google Scholar
• Novartis A-G, Switz. The treatment of diseases such as hyperlipidemia or arteriosclerosis. CN101878199A. 2010.
   Google Scholar
• Novartis A-G, Switz. Organic compounds. US8759365B2. 2014.
   Google Scholar
• Novartis A-G, Switz. Method of treating atherosclerosis in high triglyceride subjects. US20140134262A1. 2014.
   Google Scholar
• Dr. Reddy’s Laboratories, Ltd, Preparation of 5-benzylaminomethyl-6-aminopyrazolo[3,4-b]pyridine derivatives as cholesteryl ester-transfer protein (CETP) inhibitors useful for treating atherosclerosis. WO2013046045A1. 2013.
   Google Scholar
• Dr. Reddy’s Laboratories Ltd. 5-benzylaminomethyl-6-aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester-transfer protein (CETP) inhibitors useful for the treatment of atherosclerosis. US9000007B2. 2015.
   Google Scholar
• Dr. Reddy’s Laboratories Ltd, Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (CETP) inhibitors WO2013024358A2. 2015.
   Google Scholar
• Dr. Reddy’s Laboratories Ltd, Preparation of cycloalkylpyridin-2-amines as cholesteryl ester-transfer protein (CETP) inhibitors for increasing HDL cholesterol and decreasing LDL cholesterol. WO2013024358A2. 2013.
   Google Scholar
• Dr. Reddy’s Laboratories Ltd, Pharmaceutical compositions of CETP inhibitors. WO2014076568A2. 2014.
   Google Scholar
• Dr. Reddy’s Laboratories Ltd, Pharmaceutical compositions of CETP inhibitors. US20160000799A1. 2016.
   Google Scholar
• Dr. Reddy’s Laboratories Ltd, Pharmaceutical compositions of CETP inhibitors. US20170071930A1. 2017.
   Google Scholar
• Dr. Reddy’s Laboratories Ltd. Pharmaceutical compositions of CETP inhibitors. WO2014128564A2. 2014.
   Google Scholar
• Merck Sharp & Dohme Corp, Benzopiperazine derivatives as CETP inhibitors and their preparation. WO2013028382A1. 2013.
   Google Scholar
• Merck Sharp & Dohme Corp, Substituted benzopiperazines as CETP inhibitors. US9126976B2. 2015.
   Google Scholar
• Merck Sharp & Dohme Corp, 3,3ʹ-Disubstituted indolines as inhibitors of Cholesterol Ester Transfer Protein. WO2015054088A1. 2015.
   Google Scholar
• Merck Sharp & Dohme Corp. 3,3ʹ-Disubstituted indolines as inhibitors of Cholesterol Ester Transfer Protein. US9688630B2. 2017.
   Google Scholar
• Wilson JE, Kurukulasuriya R, Reibarkh M, et al. Discovery of Novel Indoline Cholesterol Ester Transfer Protein Inhibitors (CETP) through a structure-guided approach. ACS Med Chem Lett. 2016;7(3):261–265.
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme Corp., USA, Preparation of tetrahydropyrrolooxazolidinones as CETP inhibitors. WO2013063217A1. 2013.
   Google Scholar
• Merck Sharp & Dohme Corp., USA, Bicyclic ureas and thiadiazolidine-1,1-dioxides as CETP inhibitors. WO2015017302A2. 2015.
   Google Scholar
• Merck Sharp & Dohme Corp., USA, Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein and their preparation. US9663534B2. 2017.
   Google Scholar
• Merck Sharp & Dohme Corp, Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein and their preparation. WO2015094932A1. 2015.
   Google Scholar
• Merck Sharp & Dohme Corp, Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein and their preparation. WO2017011279A1. 2017.
   Google Scholar
• Merck Sharp & Dohme Corp, Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein and their preparation. US20140378493A1. 2014.
   Google Scholar
• Merck Sharp & Dohme Corp, Cyclic amine-substituted oxazolidinones as CETP inhibitor and their preparation. WO2012058187A1. 2012.
   Google Scholar
• Merck Sharp & Dohme Corp, Preparation of phenylazetidinylpyrimidinyl methyl oxazolidinone derivatives and analogs for use as CETP inhibitors. WO2013165854A1. 2013.
   Google Scholar
• Merck Sharp & Dohme Corp, Cyclic amine-substituted oxazolidinones as CETP inhibitor and their preparation. US20150111866A1. 2015.
   Google Scholar
• Merck Sharp & Dohme Corp, Cyclic amine-substituted oxazolidinones as CETP inhibitor and their preparation. US9221834B2. 2015.
   Google Scholar
• Merck Sharp & Dohme Corp. Process for a CETP inhibitor. WO2013066768A1 (2013).
   Google Scholar
• Merck Sharpe & Dohme Corp. Process for synthesizing a CETP inhibitor. US9145348B2 (2015).
   Google Scholar
• Merck Sharp & Dohme Corp, Prodrugs of oxazolidinone compounds that are cholesteryl ester transfer protein inhibitors. WO2010039474A1. 2010.
   Google Scholar
• Merck Sharp & Dohme Corp, Preparation of spirocyclic CETP inhibitors. WO2014099836A1. 2014.
   Google Scholar
• Merck Sharp & Dohme Corp, Spirocyclic CETP inhibitors. US20150342931A1. 2015.
   Google Scholar
• Chong Kun Dang Pharmaceutical Corp, Cycloalkenyl aryl derivatives for CETP inhibitor. WO2012141487A2. 2012.
   Google Scholar
• Chong Kun Dang Pharmaceutical Corp, Biaryl- or heterocyclic biaryl-substituted cyclohexene compounds as CETP inhibitors. WO2014119947A1. 2014.
   Google Scholar
• Chong Kun Dang Pharmaceutical Corp, Biaryl- or heterocyclic biaryl-substituted cyclohexene compounds as CETP inhibitors. US20160237046A9. 2016.
   Google Scholar
• Dong-A ST Co., Ltd, Oxazolidinone derivatives as CETP inhibitor, its preparation method, and pharmaceutical composition comprising the same. US9533977B2. 2017.
   Google Scholar
• Dong-A ST Co., Ltd, Oxazolidinone derivatives as CETP inhibitor, its preparation method, and pharmaceutical composition comprising the same. WO2014157994A1. 2014.
   Google Scholar
• Daiichi Sankyo Company, Acid addition salt of substituted pyridine compound. US9321747B2. 2016.
   Google Scholar
• Daiichi Sankyo Company, Preparation of tetrahydroquinoline compounds as CETP inhibitors. WO2012005343A1. 2012.
   Google Scholar
• Daiichi Sankyo Company, Preparation of substituted pyridine-acid adducts as CETP inhibitors. WO2013103150A1. 2013.
   Google Scholar
• Hoffmann-La Roche AG, Switz.; Hoffmann-La Roche Inc. CETP modulator for use in the treatment of eye disease. WO2015091410A1. 2015.
   Google Scholar
• Hoffmann-La Roche AG, Switz. Cyclohexanecarboxamide derivatives as inhibitors of cholesteryl ester transfer protein and their preparation and use for the treatment of CETP-mediated diseases. WO2010069859A1. 2010.
   Google Scholar
• Boehringer Ingelheim International GmbH, Preparation of tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation. WO2011101424A1. 2011.
   Google Scholar
• Boehringer Ingelheim International GmbH, Tricyclic pyridine derivatives as CETP inhibitors and their preparation. WO2012110599A1. 2012.
   Google Scholar
• Bayer Healthcare A-G, Preparation of a quinolinol derivative useful for the treatment of cardiovascular diseases and as an inhibitor of cholesterol ester transfer protein. DE102004061000A1. 2006.
   Google Scholar
• Trieselmann T, Wagner H, Fuchs K, et al. Potent cholesteryl ester transfer protein inhibitors of reduced lipophilicity: 1,1ʹ-spiro-substituted hexahydrofuroquinoline derivatives. J Med Chem. 2014;57(21):8766–8776.
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company, Trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid for treatment of cardiovascular diseases. US20100331309A1. 2010.
   Google Scholar
• Dexa Medica PT, Phaleria macrocarpa extract, extraction process and its use as cholesteryl ester transferase protein (CETP) inhibitor. WO2012143872A1. 2012.
   Google Scholar
• Pt. Dexa Medica, Phaleria macrocarpa extract, extraction process and its use as cholesteryl ester transferase protein (CETP) inhibitor. US8999404B2. 2015.
   Google Scholar
• Shanghai Hengrui Pharmaceuticals Co., Ltd. Preparation of oxazolidinone derivatives as cholesterol ester transfer protein inhibitors for treatment of hyperlipidemia and atherosclerosis. CN101412711A. 2009.
   Google Scholar
• Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd. Benzo-seven-member heterocyclic derivative as cholesteryl ester transfer protein inhibitor and its preparation. WO2014012401A1. 2014.
   Google Scholar
• Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd, Oxazolidinone derivative as CETP inhibitor and its preparation. WO2014012428A1. 2014.
   Google Scholar
• China Pharmaceutical University, Pentacyclic triterpene as cholesteryl ester transfer protein inhibitor and its preparation. WO2016086453A1. 2016.
   Google Scholar
• Chang Y, Zhou S, Li E, et al. Fragment-based discovery of novel pentacyclic triterpenoid derivatives as cholesteryl ester transfer protein inhibitors. Eur J Med Chem. 2017;126:143–153.
   PubMed Web of Science ®Google Scholar
• Nanjing Huamai Biopharmaceutical Technology Co., Ltd, Formononetin derivative, preparation method, and medicinal use thereof. CN106146450A. 2016.
   Google Scholar
• China Pharmaceutical University, Preparation of isoflavone amide derivatives as cholesterol ester transfer protein inhibitors. CN105541777A. 2016.
   Google Scholar
• Shenyang Pharmaceutical University, 3-(N,N-disubstituted amino)propanamide derives, preparation method thereof, and use thereof in medicine. WO2017041665A1. 2017.
   Google Scholar
• Zhao D, Xie H, Bai C, et al. Design, synthesis and biological evaluation of N,N-3-phenyl-3-benzylaminopropanamide derivatives as novel cholesteryl ester transfer protein inhibitor. Bioorgan Med Chem. 2016;24(8):1589–1597.
   PubMed Web of Science ®Google Scholar
• Xie H, Li Y, Bai C, et al. Discovery of novel N,N-3-phenyl-3-benzylaminopropionanilides as potent inhibitors of cholesteryl ester transfer protein in vivo. Bioorgan Med Chem. 2016;24(8):1811–1818.
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol. 1995;75(17):1196.
   PubMed Web of Science ®Google Scholar
• Group TBS. Effects of dalcetrapib in patients with a recent acute coronary syndrome — NEJM. N Eng J Med. 2012;367(22):2089–2099.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Brewer HB, Kastelein JJP, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. Jama. 2011;306(19):2099–2109.
   PubMed Web of Science ®Google Scholar
• Krishna R, Gheyas F, Liu Y, et al. Chronic administration of anacetrapib is associated with accumulation in adipose and slow elimination. Clin Pharmacol and Ther. 2017;102(5):832–840.
   PubMed Web of Science ®Google Scholar
• Hovingh GK, Kastelein JJP, Deventer SJHV, et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2015;386(9992):452–460.
   PubMed Web of Science ®Google Scholar
• Liu S, Mistry A, Reynolds JM, et al. Crystal structures of cholesteryl ester transfer protein in complex with inhibitors. J Biol Chem. 2012;287(44):37321–37329.
   PubMed Web of Science ®Google Scholar
• Group HTRC, Bowman L, Hopewell JC, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Eng J Med. 2017;377(13):1217–1227.
   PubMed Web of Science ®Google Scholar
• White J, Swerdlow DI, Preiss D, et al. Association of lipid fractions with risks for coronary artery disease and diabetes. Jama Cardio. 2016;1(6):692–699.
   PubMed Web of Science ®Google Scholar
• Rader DJ, Tall AR. The not-so-simple HDL story: is it time to revise the HDL cholesterol hypothesis? Nat Med. 2012;18(9):1344–1346.
   PubMed Web of Science ®Google Scholar